Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry

被引:21
作者
Ajani, Andrew E. [1 ,10 ]
Reid, Christopher M. [9 ]
Duffy, Stephen J. [5 ]
Andrianopoulos, Nick [9 ]
Lefkovits, Jeffrey
Black, Alexander [4 ]
New, Gishel [3 ]
Lew, Robert [2 ]
Shaw, James A. [5 ]
Yan, Bryan P. [6 ,7 ]
Gurvitch, Ronen
Al-Fiadh, Ali [8 ]
Brennan, Angela L. [9 ]
Clark, David J. [8 ]
机构
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] Frankston Hosp, Melbourne, Vic, Australia
[3] Box Hill Hosp, Melbourne, Vic, Australia
[4] Geelong Hosp, Geelong, Vic, Australia
[5] Alfred Hosp, Melbourne, Vic, Australia
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Austin Hosp, Melbourne, Vic 3084, Australia
[9] Monash Univ, Dept Epidemiol & Prevent Med, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia
[10] Royal Melbourne Hosp, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
D O I
10.5694/j.1326-5377.2008.tb02113.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine short-and medium-term outcomes of percutaneous coronary interventions (PCIs), with a focus on comparing drug-eluting stents (DESs) with bare-metal stents (BMSs). Design, setting and participants: Retrospective analysis of data from the Melbourne Interventional Group (MIG) registry, a large multicentre Australian registry. The study cohort consisted of 6364 consecutive patients undergoing 7167 PCIs between April 2004 and August 2007. Main outcome measures; Clinical events including death, myocardial infarction.(MI), target lesion revascularisation (TLR), target vessel revascularisation (TVR) and major adverse cardiac events (MACE) (a composite of death, MI and TVR), at 30 days and at 12 months. Results: The cohort was predominantly male (74%), with a mean age of 64.7 years (SD, 12.0 years). DESs were used in 3482 (51.4%) of PCIs. In the overall cohort, rates of clinical events were low at 30 days: mortality (1.9%), MI (2.4%), TLR (2.0%), TVR (2.4%) and MACE (5.7%). At 12 months, event rates were: mortality (5.2%), MI (6.0%), TLR (5.8%), TVR (8.2%) and MACE (16.2%). Patients receiving DESs had similar mortality rates to those receiving BMSs (4.0% v 6.0%; P = 0.62 [propensity score-adjusted]); late thrombosis rates were also similar in the two groups (0.8% v 1.1%; P = 0.38). The proportion of patients receiving DESs fell significantly over time, from 54.9% in the first 24 months to 44.7% in the last 15 months of the study period (P < 0.01). Independent predictors of 12-month mortality included diabetes, renal failure, ST-segment-elevation MI and cardiogenic shock. Conclusion: Our clinical event rates were comparable with international registry outcomes. Rates of mortality and stent thrombosis were no higher in patients with DESs than those with BMSs. Although DESs were used in about half the procedures (preferentially for higher-risk lesions), recent trends suggest their use is in decline.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 30 条
[1]  
Ajani A E, 2006, Heart Lung Circ, V15, P44, DOI 10.1016/j.hlc.2005.08.001
[2]  
*AUSTR I HLTH WELF, 2004, 27 CVD AIHW NAT HEAR
[3]   Postmarket surveillance for drug-eluting coronary stents - A comprehensive approach [J].
Baim, DS ;
Mehran, R ;
Kereiakes, DJ ;
Gross, TP ;
Simons, M ;
Malenka, D ;
Kaplan, AV .
CIRCULATION, 2006, 113 (06) :891-897
[4]   Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions [J].
Colombo, A ;
Drzewiecki, J ;
Banning, A ;
Grube, E ;
Hauptmann, K ;
Silber, S ;
Dudek, D ;
Fort, S ;
Schiele, F ;
Zmudka, K ;
Guagliumi, G ;
Russell, ME .
CIRCULATION, 2003, 108 (07) :788-794
[5]   Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:: data from a large two-institutional cohort study [J].
Daemen, Joost ;
Wenaweser, Peter ;
Tsuchida, Keiichi ;
Abrecht, Linda ;
Sophia, Vaina ;
Morger, Cyrill ;
Kukreja, Neville ;
Jueni, Peter ;
Sianos, Georgios ;
Hellige, Gerrit ;
van Domburg, Ron T. ;
Hess, Otto M. ;
Boersma, Eric ;
Meier, Bernhard ;
Windecker, Stephan ;
Serruys, Patrick W. .
LANCET, 2007, 369 (9562) :667-678
[6]   Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents - A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians [J].
Grines, Cindy L. ;
Bonow, Robert O. ;
Casey, Donald E., Jr. ;
Gardner, Timothy J. ;
Lockhart, Peter B. ;
Moliterno, David J. ;
O'Gara, Patrick ;
Whitlow, Patrick .
CIRCULATION, 2007, 115 (06) :813-818
[7]   Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions [J].
Grube, E ;
Silber, S ;
Hauptmann, KE ;
Mueller, R ;
Buellesfeld, L ;
Gerckens, U ;
Russell, ME .
CIRCULATION, 2003, 107 (01) :38-42
[8]   Thrombosis and drug-eluting stents - An objective appraisal [J].
Holmes, David R., Jr. ;
Kereiakes, Dean J. ;
Laskey, Warren K. ;
Colombo, Antonio ;
Ellis, Stephen G. ;
Henry, Timothy D. ;
Popma, Jeffrey J. ;
Serruys, Patrick W. J. C. ;
Kimura, Takeshi ;
Williams, David O. ;
Windecker, Stephan ;
KrucofF, Mitchell W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (02) :109-118
[9]   Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries - A serial volumetric intravascular ultrasound analysis from the ASian paclitaxel-eluting stent clinical trial (ASPECT) [J].
Hong, MK ;
Mintz, GS ;
Lee, CW ;
Song, JM ;
Han, KH ;
Kang, DH ;
Song, JK ;
Kim, JJ ;
Weissman, NJ ;
Fearnot, NE ;
Park, SW ;
Park, SJ .
CIRCULATION, 2003, 107 (04) :517-520
[10]   Late and very late thrombosis of drug-eluting stents - Evolving concepts and perspectives [J].
Jaffe, Ronen ;
Strauss, Bradley H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (02) :119-127